News

Analysts Maintain Positive Outlook on FactSet's Earnings Growth

Analysts Maintain Positive Outlook on FactSet's Earnings Growth

Analysts Keep Positive View on FactSet's Earnings Growth

BMO Capital has reaffirmed its Market Perform rating for FactSet Research Systems (NYSE:FDS), maintaining a price target of $440.00. Their analysis pointed out that FactSet's latest earnings report featured an adjusted earnings per share (EPS) that outperformed expectations, thanks to impressive margins.

Looking at the year-over-year performance, the company showed stability with an organic revenue increase of about 5%. However, its organic Annual Subscription Value (ASV) growth rate did show a slight deceleration.

In an important update, FactSet has issued its first outlook for the fiscal year 2025, which aligns with the upper end of consensus estimates. Additionally, the company announced an investor day scheduled for November, offering stakeholders an excellent chance to gain insights into its strategic plans and overall performance.

Following the earnings report, shares of FactSet Research Systems experienced positive movement in pre-market trading. This market reaction suggests a favorable interpretation of the company’s performance and the investor day announcement, as indicated by the stock’s pre-open activity.

As the investor day approaches, both investors and analysts are eager to hear more about the company’s future strategies. It’s worth noting that FactSet won’t be updating any of its forecasts until its first-quarter earnings for the fiscal year 2025 are released.

FactSet recently reported strong fourth-quarter results that exceeded analyst expectations. Its adjusted EPS reached $3.74, surpassing the $3.62 consensus, while revenue grew by 4.9% year-over-year, totaling $562.2 million—again exceeding the expected $546.76 million.

The company's ability to maintain strong operating margins was clear, as FactSet’s adjusted operating margin increased to 35.8%, up from 33.4% the prior year, driven primarily by lower compensation costs.

On a different note, Wolfe Research has issued an underperform rating for FactSet shares. This stems from concerns about management’s commentary on revenue growth projections and the various factors affecting year-over-year margin trends.

Despite this, Wolfe Research did indicate that FactSet’s client and user base has grown compared to the fourth fiscal quarter of 2023, hinting at an improving demand landscape for the company’s services.

FactSet's earnings guidance for fiscal 2025 stands at $16.80-$17.40 per share, which is slightly different from the Wall Street average of $17.36. Notably, the company's revenue forecast of $2.29-$2.31 billion aligns well with the consensus estimate of $2.30 billion, reinforcing its resilient performance in the face of market fluctuations.

InvestingPro Insights

If you’re interested in examining FactSet Research Systems’ financial position, InvestingPro offers real-time insights. The company has a solid market capitalization of $17.0 billion, along with a P/E ratio of 33.36, suggesting a premium valuation.

It's also worth noting its PEG ratio of 17.74, which indicates the premium being paid for growth relative to its current earnings. Despite this high valuation, FactSet has shown a strong commitment to returning value to shareholders by increasing its dividend for 26 consecutive years, resulting in a current dividend yield of 0.93%.

The company continues to demonstrate strong revenue growth, achieving a 6.23% year-over-year increase as of Q3 2024, which supports the positive trends observed in its recent earnings report. Moreover, FactSet’s gross profit margin stands at an impressive 53.26%, showing the company’s capability to thrive while expanding its market presence.

Experts point out that while FactSet's current trading metrics show a high earnings multiple and elevated P/E ratio compared to short-term earnings growth, its historical performance has yielded solid returns over the last decade. This track record may be attractive to long-term investors weighing the company's future prospects.

This article was generated with AI assistance and has been reviewed for accuracy. For additional details, please refer to the terms and conditions.

Frequently Asked Questions

What is the current stock target for FactSet?

The current stock target for FactSet Research Systems (NYSE:FDS) is set at $440.00 by BMO Capital.

How did FactSet perform in its recent earnings report?

FactSet reported an adjusted earnings per share of $3.74, which exceeded analyst expectations, along with a revenue total of $562.2 million, surpassing forecasts.

What are FactSet's revenue growth expectations for fiscal 2025?

For fiscal 2025, FactSet expects its revenue to fall between $2.29 billion and $2.31 billion, closely aligning with industry consensus.

When is FactSet’s upcoming investor day scheduled?

The investor day for FactSet Research Systems is scheduled for November 14, 2024.

How has FactSet's dividend policy contributed to its appeal?

FactSet has increased its dividend for 26 consecutive years, highlighting its dedication to returning value to shareholders, which translates to a dividend yield of 0.93%.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

DNOW Faces Class Action: Proxy Missteps Under Fire

Updated Category News Views 1

DNOW's Rough Patch: Investors, Beware Here's a tangled mess for you: DNOW Inc., a name that should've been cruising post-merger, now finds itself smack in the middle of a class action lawsuit. Blame it on some botched acquisition moves with MRC Global Inc. The suits claim DNOW's management may have played fast and loose with the truth during their big merger spiel. When...

Continue Reading
GBC 2026 Wraps Up: Korea Eyes Bio Industry Leadership

Updated Category News Views 3

GBC 2026: Korea's Giant Leap in Bio Innovation Well, there wasn't a dull moment at the 'Global Bio Conference 2026' in Seoul. Picture a melting pot where 5,600 participants from 19 countries converged to chat about the latest and greatest in biopharma innovation and regulatory strategies. That's not a setup you see every day, mind you. This event packed the room with...

Continue Reading
AION UT Sets New Safety Standard in Euro NCAP 2026

Updated Category News Views 3

The New Gold Standard in Safety for Small EVs Hop into your favorite auto forum and you'll hear more than a buzz—it's a full-blown ruckus. The reason? GAC’s AION UT just nabbed a 2026 Euro NCAP Five-Star Safety Rating. Now, this isn’t just another accolade in a crowded trophy room; it’s a statement, a seismic shift in how small electric vehicles stack up in terms...

Continue Reading
Nuix Leverages AI for Transformative Legal Review

Updated Category News Views 1

Nuix Unveils AI Innovations in Legal Review Diving headfirst into the evolving world of legal technology, Nuix has just rolled out some serious upgrades to its eDiscovery toolkit. By plucking AI right out of the data science ethers, they're not just dabbling in futuristic tech—they're planting generative AI at the heart of legal review on their SaaS platform, Nuix...

Continue Reading
VEVOR Unveils New Products at IFA Berlin 2026

Updated Category News Views 2

VEVOR's Bold Display at IFA Berlin VEVOR isn't shy about making waves at IFA Berlin 2026. The global home improvement heavyweight decided to go all out with an interactive booth that's hard to miss, giving visitors a real taste—sometimes literally—of what they’ve got to offer. This hands-on approach isn't just a gimmick; it’s a clever move to solidify VEVOR's...

Continue Reading
Kean-NJCU Merger: A Strategic Educational Move

Updated Category News Views 3

The clock's ticked for Kean University and New Jersey City University, landing them into a fusion that's set tongues wagging across the education sector. This ain't just another day at the park—it’s a significant shift in the academic landscape that deserves a closer, sharper look. Behind the Curtains of Strategic Planning So, who’s behind the wheel charting this...

Continue Reading
AB SKF to Hold EGM, Spin Off Automotive Assets

Updated Category News Views 3

SKF's Extraordinary Meeting: A Pivotal Moment AB SKF, a heavyweight in the industrial technology sector, is summoning its shareholders for an Extraordinary General Meeting on October 1, 2026. The venue? The Elite Park Avenue Hotel in Gothenburg, Sweden—sounds fancy, but don't expect to hear a string quartet at this shindig. What's truly on the agenda is a critical...

Continue Reading
La Compagnie Unveils NYC-Düsseldorf Flight Plans

Updated Category News Views 2

A new chapter is unfolding in the skies over the Atlantic. La Compagnie is gearing up to connect New York to Düsseldorf with a direct, all-business-class flight starting in Spring 2027. This move is ambitious, tapping into the bustling economic energy present across the North Rhine-Westphalia region—an economic powerhouse littered with U.S.-affiliated businesses. A...

Continue Reading
53% of European Telecom Users Eye Provider Switch

Updated Category News Views 3

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Continue Reading
Papa John's Faces Investor Lawsuit: Class Action Looms

Updated Category News Views 1

Papa John's in Hot Water Again? Look, just when you think the pizza game is all dough and cheesy goodness, along comes a legal scuffle to toss our assumptions. Bronstein, Gewirtz & Grossman, LLC has slapped a class action lawsuit against Papa John's International, Inc. (NASDAQ: PZZA), claiming the company and some of its higher-ups haven't been playing fair with the...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Developments in Gene Therapy Presented by Genprex

Updated Category News Views 67

Exciting Data Presentation on Reqorsa Gene Therapy Genprex, Inc. (NASDAQ: GNPX), a pioneering clinical-stage gene therapy company, is set to have its research collaborators present groundbreaking preclinical data on their innovative Reqorsa gene therapy. The presentation will occur at a prominent annual meeting dedicated to immunotherapy, underscoring the potential of...

Continue Reading
ONWARD Medical's ARC-EX System Recognized as Top Innovation

Updated Category News Views 190

ONWARD Medical's ARC-EX System Recognized ONWARD Medical N.V. has garnered significant attention with its ARC-EX System being acknowledged as one of TIME's Best Inventions. This medical technology firm, engaged in developing groundbreaking therapies aimed at restoring movement, function, and independence for individuals grappling with spinal cord injuries (SCI), has truly...

Continue Reading
Legal Insights for Investors Facing Semler Scientific Claims

Updated Category News Views 232

Understanding the Claims Against Semler Scientific Investors of Semler Scientific, Inc. are currently facing significant uncertainties as the company navigates potential legal claims. Faruq & Faruq, LLP, a prominent securities law firm, is taking the lead in addressing these concerns. If you are among those who acquired securities in Semler Scientific, your rights may be...

Continue Reading
Unveiling ATX's Innovative 1.8GHz Amplifiers at SCTE TechExpo

Updated Category News Views 106

ATX Showcases Innovative 1.8GHz Amplifiers at TechExpo ATX Networks, a prominent player in broadband access and media distribution solutions, is preparing to unveil its state-of-the-art technology at the upcoming SCTE TechExpo. This year, the spotlight will be on their GigaXtend™ 1.8GHz HFC amplifiers, which boast two-way communication capabilities designed to boost...

Continue Reading
Sanofi's Tolebrutinib Shows Promise in Multiple Sclerosis Trials

Updated Category News Views 99

Exciting Developments in Multiple Sclerosis Treatment Sanofi SA, a major player in healthcare, recently released promising data from the HERCULES phase 3 study that focuses on the effectiveness of tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS). This groundbreaking treatment is gaining attention, as it appears to delay the...

Continue Reading